Synopsis:
Nureca Limited, a Healthcare Stock, reports 21% YoY revenue growth and a 384% QoQ net profit surge in Q2 FY26 results
This Healthcare stock, engaged in the business of home healthcare and wellness products, offering a wide range of medical devices and digital health solutions for chronic disease management, orthopaedic care, and mother and baby care, hit a 20 percent upper circuit after the company reported September quarterly results with a 348 percent QoQ increase in net profit.
With a market capitalization of Rs. 288.96 crores, the shares of Nureca Limited hit a 20 percent upper circuit of Rs. 288.95 per share on Friday, up from its previous closing price of Rs. 240.80 per share.
Q2 FY26 Result Walkthrough
Coming into the quarterly results of Nureca Limited, the company’s consolidated revenue from operations increased by 21 percent YOY, from Rs. 31.19 crore in Q2 FY25 to Rs. 37.74 crore in Q2 FY26, and grew by 10.42 percent QoQ from Rs. 34.18 crore in Q1 FY26.
In Q2 FY26, Nureca Limited’s consolidated net profit has turned from negative to positive, reaching a net profit of Rs. 3.63 crore compared to a net loss of Rs. 0.48 crore during the same period last year. As compared to Q1 FY26, the net profit has increased by 348.15 percent, from Rs. 0.81 crore.
Further, the company’s EBITDA has increased by 600 percent, from Rs. 0.80 crore in Q2 FY25 to Rs. 5.60 crore in Q2 FY26. The basic earnings per share increased by 348.15 percent and stood at Rs. 3.63 as against Rs. 0.81 recorded in the previous quarter in the financial year 2026.
Company Overview
Nureca Limited was incorporated in 2016 and is a leading Indian company specializing in home healthcare and wellness products. The company’s flagship brands include Dr Trust, Dr Physio, and Trumom, which offer a wide range of products such as chronic disease management devices, orthopaedic solutions, mother and baby care products, and personal fitness equipment.
Nureca’s products are designed to be accurate, user-friendly, and compliant with global quality standards, including USFDA and CE certifications, with over 50 USFDA-approved products and extensive patents. Nureca operates with a strong direct-to-consumer (D2C) business model and has achieved notable reach with over 12 million customers globally in five countries.
Nureca Limited is a leading Indian healthcare company offering 277 SKUs, including nebulizers, massagers, and sanitizers. In Q1 FY26, it launched six new affordable, high-quality products to meet everyday health needs.
With an annual capacity of 8 lakh units, Nureca combines a strong e-commerce presence on Amazon, Flipkart, Zepto, Blinkit, Tata 1mg, and Nykaa with more than 192 distributors and more than 52 sales staff across 23 states, ensuring a wide reach and customer trust.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
